Why the study?
Does the intraindividual blood pressure response to lisinopril differ from telmisartan in untreated hypertensive patients?
Does the intraindividual blood pressure response to lisinopril differ from telmisartan in untreated hypertensive patients?
While overall blood pressure reductions are similar between ACE inhibitors and ARBs, individual patient responses can vary significantly, suggesting one class may be effective when the other fails.
Answers are grounded in this paper and cite their sources.
Variable intraindividual responses support sequential ACEI-ARB trials in nonresponders; extends evidence for personalized antihypertensive selection.
This study aims to test the hypothesis that in some hypertensive subjects the blood pressure (BP) response to angiotensin‐converting enzyme inhibition differs from that to angiotensin receptor blockade (ARB); a responder to angiotensin‐converting enzyme inhibition may not respond to ARB or the opposite. A randomized, open‐label, crossover, comparative trial of lisinopril 20 mg compared with telmisartan 80 mg (5 weeks per treatment period) was conducted in 32 untreated hypertensives using 24‐hour ambulatory BP monitoring. Subjects were classified as “responders” and “nonresponders” using an arbitrary threshold of ambulatory BP response (≥10 mm Hg systolic or ≥5 diastolic) or the median response achieved by each drug. No difference was detected between the drugs in their effect on ambulatory BP (mean difference 1.2±7.1/0.7±5.1 mm Hg, systolic/diastolic). Significant correlations were found between the antihypertensive responses to the two drugs (r=0.77, p <0.001). Using the arbitrary response criterion, there was a difference between the drugs in the responses in 28%/13% of subjects (9/4 patients) for systolic/diastolic BP (19%/25% using the median response criterion). These data suggest that in some hypertensive patients the BP response to angiotensin‐converting enzyme inhibition may fail to predict the response to ARB. It appears that there are differences in the antihypertensive action of angiotensin‐converting enzyme inhibitors and ARBs that may be clinically important.
No takes yet. Share an insight, caveat, or question.
Stergiou et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: